As the official partner of AmoyDx, Epinode provides the ROS1 Gene Fusion Detection Kit, a companion diagnostic tool designed to aid in selecting targeted therapy (crizotinib (Xalkori)) for non-small cell lung cancer (NSCLC) patients. The AmoyDx® ROS1 Gene Fusions Detection Kit is a real-time PCR assay. It allows for qualitative detection of up to 14 ROS1 gene fusions in human RNA extracted from formalin-fixed paraffin-ded (FFPE) tumor tissue. This kit is intended to assist in identifying the ROS1 fusion status for patients with non-small cell lung cancer (NSCLC) who may qualify for approved targeted therapies. It is intended for in vitro diagnostic use and should be operated by trained professionals in a laboratory setting. AmoyDx's ROS1 Companion Diagnostic Test is the first ROS1 gene fusion detection kit in Korea, allowing the selection of crizotinib (Xalkori) as a treatment option for NSCLC patients. Epinode plans to expand beyond ROS1 testing in NSCLC to enter the growing market for EGFR and KRAS mutation diagnostics.